Steven Feldman, MD, PhD, and Jonathan Silverberg, MD, PhD, MPH, provide their clinical insights into the burden of disease experienced by persons with atopic dermatitis and strategies for management. They discuss how improved understanding of pathophysiologic mechanisms has led to the availability of new topical and systemic therapies that, when integrated with other therapies, can reduce patients’ disease burden. They also discuss 6 medications in late-stage development for atopic dermatitis.

Content Areas

  • Burden of disease
  • Pathophysiologic mechanisms
  • Basic management
  • Topical therapies
  • Systemic therapies
  • Emerging therapies

Target Audience

This activity was developed for national audience (US) dermatologists, pediatric dermatologists, allergists, along with nurse practitioners and physician assistants within those specialties who manage patients with atopic dermatitis.

Faculty

Steven R. Feldman, MD, PhD
Steven R. Feldman, MD, PhD
Professor of Dermatology, Pathology and Public Health Sciences
Department of Dermatology
Wake Forest School of Medicine
Winston-Salem, North Carolina
Jonathan Silverberg, MD, PhD, MPH
Jonathan Silverberg, MD, PhD, MPH
Director, Northwestern Medicine Multidisciplinary Eczema Center
Director, Contact Dermatitis Clinic
Northwestern Memorial Hospital
Associate Professor, Departments of Dermatology, Preventive Medicine and Medical Social Sciences
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Enter your information to begin.
CME Credit
Available Credit: 1.75 AMA PRA Category 1 Credits™.
1.75 AANP Contact Hours
Opens: March 31, 2019
Expires: March 30, 2020
Target Audience: Dermatologists
Allergists
Nurse Practitioners
Physician Assistants
Other Health Care Providers
This activity is supported by an independent educational grant from Pfizer.